The FDA's drug approvals database lists a supplement dated 15 September 2026 to an abbreviated new drug application (ANDA 214020) for tigecycline, held by Meitheal. Tigecycline is an intravenous antibacterial.
The database entry does not say what the supplement changed, and nothing in the record points to a safety finding or a new indication. A supplement to a generic application can cover manufacturing, labelling or administrative changes. For a prescriber, the entry is a prompt to check the current product information if you use this brand, not a reason to change practice. The FDA is the authority; no CDSCO position is stated here.
- The FDA entry is a supplement to a generic application; its content is not described in the record.
- Check the current product information if you stock this generic.
- No change to tigecycline use is indicated by this entry alone.
Why it matters
Regulatory entries vary from safety alerts to paperwork, and this one gives no reason to change how tigecycline is used.
Don't overread it
A supplement to a generic application is not a new indication or a safety communication.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for infectious diseases, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free